Elezanumab Drug Asset Due Diligence Report 2026

This Elezanumab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Elezanumab can convert its Monoclonal antibody profile and RGMa biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Elezanumab (query alias: Elezanumab)
Modality / target	Monoclonal antibody; RGMa; RGMa inhibitors, Immunomodulators, Myelin proteins stimulants
Highest global status	Phase 2
Originator	AbbVie, Inc.
Active developers	AbbVie, Inc.

The MCP disease footprint includes Acute Ischemic Stroke. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT04309474	Phase 2	Completed	121	Primary endpoint not disclosed in English source
NCT04295538	Phase 2	Completed	60	Primary endpoint not disclosed in English source
NCT04278235	Not Applicable	No longer available	Not disclosed	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Ischemic Stroke

Phase 2; n=121; evaluation: Not stated in English source. Reported fields: Analysis of the National Institutes of Health Stroke Scale (NIHSS) Total Score Area Under the Curve During the Treatment Period(LS Mean) = 3.83 Unit (95%CI, 2.642 - 5.024); Analysis of the National Institutes of Health Stroke Scale (NIHSS) Total Score Area Under the Curve During the Treatment Period(LS Mean) = 3.13 Unit (95%CI, 1.938 - 4.317)

Longitudinal Biomarker Analysis in Patients With Ischemic Stroke: Exploratory Targeted and Omics Assessments From a Phase 2a Clinical Trial

Phase 2; n=not disclosed; evaluation: Positive. Reported fields: GFAP concentrations = 746.0 pg/mL ; GFAP concentrations = 746.0 pg/mL

A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

Phase 2; n=208; evaluation: Not stated in English source. Reported fields: Mean Overall Response Score (ORS) at Week 52(LS Mean) = 0.04 Point ; Mean Overall Response Score (ORS) at Week 52(LS Mean) = -0.17 Point

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Elezanumab addresses Acute Ischemic Stroke. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned matched transaction record(s) under the scope “target-level comparable: RGMa.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: RGMa records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
No matched asset or comparable transaction returned.

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Compositions and methods for use in KRAS-targeted therapies for the treatment of cancer”. The milestone feed surfaced a patent-application signal described as “Combination therapies and methods for myelin growth and treatment of age- related hearing loss”. The milestone feed surfaced a patent-application signal described as “Method for preparing extrahepatic vesicles/apoptosis vesicles by inducing fibroblasts to be directly reprogrammed into hepatocyte-like cells and application of extrahepatic vesicles/apoptosis vesicles”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO